Follistatin: Research Overview

Follistatin is an endogenous glycoprotein that was originally characterized as an inhibitor of follicle-stimulating hormone (FSH) secretion from the pituitary — hence the name — but whose most pharmacologically significant function for research purposes is high-affinity binding and neutralization of myostatin (GDF-8) and other members of the TGF-β family, including activin. By sequestering myostatin, follistatin removes a major brake on skeletal muscle hypertrophy, which has made it a focus of muscle disease and body-composition research. The most substantive human clinical data for follistatin involve not injection of the native protein but AAV-mediated gene therapy (AAV1-FS344) delivered to muscle in trials for Becker muscular dystrophy and inclusion body myositis conducted at Nationwide Children's Hospital. Exogenous administration of follistatin protein faces formidable pharmacokinetic barriers, and no published human dose-finding trial exists for protein-based delivery.

What is Follistatin?

Follistatin is a monomeric glycoprotein encoded by the FST gene that exists in multiple isoforms generated by alternative splicing. The two primary secreted isoforms are FST-315 (315 amino acids) and FST-344 (344 amino acids, also written FS344). FST-344 is the longer isoform and binds heparan-sulfate proteoglycans on cell surfaces, restricting its bioavailability in circulation; FST-315 circulates more freely and is thought to have broader systemic access. Research-chemical vendors typically offer lyophilized recombinant follistatin labeled as FST-344 or FLGR242. Follistatin has no approved clinical indication and is not approved by any major regulatory body for therapeutic human use. It is a large protein (MW ~31–35 kDa depending on glycosylation) that requires parenteral administration.

Mechanism of Action

Follistatin binds myostatin (GDF-8) and activin A with high affinity, forming stable non-signaling complexes that prevent these ligands from engaging their type I and type II TGF-β receptors (ACVR1B/ALK4 and ACVR2A/B). Myostatin is a negative regulator of skeletal muscle mass: loss-of-function mutations in GDF-8 in cattle and humans produce dramatic muscle hypertrophy. By neutralizing myostatin, follistatin removes this growth constraint, allowing IGF-1 and mTOR-driven hypertrophic signaling to proceed with less opposition. Follistatin also inhibits activin signaling, which influences reproductive physiology, erythropoiesis, and inflammatory cascades — effects that become relevant when considering systemic follistatin levels at supraphysiological concentrations.

What the Research Shows

The foundational case for follistatin as a muscle-mass regulator comes from preclinical work: Lee and McPherron (2001; PMC2717722) demonstrated that follistatin overexpression in mice produces massive muscle hypertrophy—a two- to three-fold increase in muscle mass—far exceeding that produced by myostatin knockout alone. This suggested follistatin also blocks additional TGF-β family members beyond myostatin. The most clinically meaningful data come from the Nationwide Children's Hospital gene-therapy program led by Jerry Mendell. Mendell et al. (2015; PMID 25322757; PMC4426808) published a phase 1/2a trial in which AAV1 carrying the FS344 construct was injected intramuscularly in Becker muscular dystrophy (BMD) patients. The intervention was generally safe, and in two subjects robust improvements in the six-minute walk test (+58 m and +125 m) were observed. A follow-up by Al-Zaidy et al. (2015; PMC5240576) confirmed functional benefit. A separate trial in sporadic inclusion body myositis also showed promising functional outcomes (Molecular Therapy, 2017).

It is important to be precise about what these trials tested: they delivered a follistatin gene via AAV to produce local, sustained follistatin expression in muscle tissue — they did not inject follistatin protein. Exogenous follistatin protein has extremely poor pharmacokinetics for systemic muscle delivery: FST-344 rapidly binds to cell-surface heparan sulfate and is cleared quickly from circulation, and the protein is too large for efficient subcutaneous absorption comparable to small peptides. No published human study has evaluated the pharmacokinetics, safety, or efficacy of subcutaneously or intramuscularly injected follistatin protein in healthy individuals or patients. Any circulating information about protein-based follistatin dosing is not grounded in published clinical data.

Reported Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Published dose-finding studies for exogenous follistatin protein in humans do not exist. The clinical trials described above used intramuscular AAV gene-therapy vectors, not protein injections, and dose is expressed as vector genomes per kilogram — not as protein milligrams. Values circulating in research-community or vendor contexts for "follistatin peptide" dosing have no peer-reviewed clinical basis and cannot be framed as established research ranges. This guide does not reproduce unvalidated dosing claims.

References

Citations for this guide are listed below. All PubMed and PMC links resolve to the NCBI abstract or full-text page for the referenced article.